世界の非ホジキンリンパ腫（NHL）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Non Hodgkin Lymphoma (NHL) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4154 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、非ホジキンリンパ腫（NHL）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（標準型、高級型）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・非ホジキンリンパ腫（NHL）の市場動向 ・企業の競争状況、市場シェア ・非ホジキンリンパ腫（NHL）の種類別市場規模（標準型、高級型） ・非ホジキンリンパ腫（NHL）の用途別市場規模（病院、診療所） ・非ホジキンリンパ腫（NHL）の北米市場規模2016-2027（アメリカ、カナダ） ・非ホジキンリンパ腫（NHL）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・非ホジキンリンパ腫（NHL）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非ホジキンリンパ腫（NHL）の中南米市場規模2016-2027（メキシコ、ブラジル） ・非ホジキンリンパ腫（NHL）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（F. Hoffmann-La Roche、Johnson & Johnson、Merck、Bristol Myers Squibb、Celgene、Eli Lilly、GlaxoSmithKline、Bayer） ・結論

Non-Hodgkin Lymphoma is the most common lymphoma which affects large number of people. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widely spreads to the other lymph nodes and to other organs such as bone marrow, lungs, or liver.

Market Analysis and Insights: Global Non Hodgkin Lymphoma (NHL) Market
The global Non Hodgkin Lymphoma (NHL) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non Hodgkin Lymphoma (NHL) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non Hodgkin Lymphoma (NHL) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non Hodgkin Lymphoma (NHL) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non Hodgkin Lymphoma (NHL) market.

Global Non Hodgkin Lymphoma (NHL) Scope and Market Size
Non Hodgkin Lymphoma (NHL) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non Hodgkin Lymphoma (NHL) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Standard
Exellent

Segment by Application
Hosptial
Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
F. Hoffmann-La Roche
Johnson & Johnson
Merck
Bristol Myers Squibb
Celgene
Eli Lilly
GlaxoSmithKline
Bayer

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Standard
1.2.3 Exellent
1.3 Market by Application
1.3.1 Global Non Hodgkin Lymphoma (NHL) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hosptial
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Non Hodgkin Lymphoma (NHL) Market Perspective (2016-2027)
2.2 Non Hodgkin Lymphoma (NHL) Growth Trends by Regions
2.2.1 Non Hodgkin Lymphoma (NHL) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non Hodgkin Lymphoma (NHL) Historic Market Share by Regions (2016-2021)
2.2.3 Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Regions (2022-2027)
2.3 Non Hodgkin Lymphoma (NHL) Industry Dynamic
2.3.1 Non Hodgkin Lymphoma (NHL) Market Trends
2.3.2 Non Hodgkin Lymphoma (NHL) Market Drivers
2.3.3 Non Hodgkin Lymphoma (NHL) Market Challenges
2.3.4 Non Hodgkin Lymphoma (NHL) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Non Hodgkin Lymphoma (NHL) Players by Revenue
3.1.1 Global Top Non Hodgkin Lymphoma (NHL) Players by Revenue (2016-2021)
3.1.2 Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Players (2016-2021)
3.2 Global Non Hodgkin Lymphoma (NHL) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non Hodgkin Lymphoma (NHL) Revenue
3.4 Global Non Hodgkin Lymphoma (NHL) Market Concentration Ratio
3.4.1 Global Non Hodgkin Lymphoma (NHL) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non Hodgkin Lymphoma (NHL) Revenue in 2020
3.5 Non Hodgkin Lymphoma (NHL) Key Players Head office and Area Served
3.6 Key Players Non Hodgkin Lymphoma (NHL) Product Solution and Service
3.7 Date of Enter into Non Hodgkin Lymphoma (NHL) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Non Hodgkin Lymphoma (NHL) Breakdown Data by Type
4.1 Global Non Hodgkin Lymphoma (NHL) Historic Market Size by Type (2016-2021)
4.2 Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Type (2022-2027)

5 Non Hodgkin Lymphoma (NHL) Breakdown Data by Application
5.1 Global Non Hodgkin Lymphoma (NHL) Historic Market Size by Application (2016-2021)
5.2 Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Non Hodgkin Lymphoma (NHL) Market Size (2016-2027)
6.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Type
6.2.1 North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021)
6.2.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027)
6.2.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2027)
6.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Application
6.3.1 North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021)
6.3.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027)
6.3.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2027)
6.4 North America Non Hodgkin Lymphoma (NHL) Market Size by Country
6.4.1 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021)
6.4.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Non Hodgkin Lymphoma (NHL) Market Size (2016-2027)
7.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type
7.2.1 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021)
7.2.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027)
7.2.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2027)
7.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application
7.3.1 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021)
7.3.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027)
7.3.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2027)
7.4 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country
7.4.1 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021)
7.4.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size (2016-2027)
8.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Type
8.2.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2027)
8.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Application
8.3.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2027)
8.4 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region
8.4.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Non Hodgkin Lymphoma (NHL) Market Size (2016-2027)
9.2 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Type
9.2.1 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021)
9.2.2 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027)
9.2.3 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2027)
9.3 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Application
9.3.1 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021)
9.3.2 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027)
9.3.3 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2027)
9.4 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country
9.4.1 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021)
9.4.2 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size (2016-2027)
10.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type
10.2.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2027)
10.3 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application
10.3.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2027)
10.4 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country
10.4.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Introduction
11.2.4 Johnson & Johnson Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Non Hodgkin Lymphoma (NHL) Introduction
11.3.4 Merck Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Details
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Introduction
11.4.4 Bristol Myers Squibb Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Celgene
11.5.1 Celgene Company Details
11.5.2 Celgene Business Overview
11.5.3 Celgene Non Hodgkin Lymphoma (NHL) Introduction
11.5.4 Celgene Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.5.5 Celgene Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Non Hodgkin Lymphoma (NHL) Introduction
11.6.4 Eli Lilly Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.6.5 Eli Lilly Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Introduction
11.7.4 GlaxoSmithKline Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.7.5 GlaxoSmithKline Recent Development
11.8 Bayer
11.8.1 Bayer Company Details
11.8.2 Bayer Business Overview
11.8.3 Bayer Non Hodgkin Lymphoma (NHL) Introduction
11.8.4 Bayer Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
11.8.5 Bayer Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Standard
Table 3. Key Players of Exellent
Table 4. Global Non Hodgkin Lymphoma (NHL) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Non Hodgkin Lymphoma (NHL) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Non Hodgkin Lymphoma (NHL) Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Non Hodgkin Lymphoma (NHL) Market Share by Regions (2016-2021)
Table 8. Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Non Hodgkin Lymphoma (NHL) Market Share by Regions (2022-2027)
Table 10. Non Hodgkin Lymphoma (NHL) Market Trends
Table 11. Non Hodgkin Lymphoma (NHL) Market Drivers
Table 12. Non Hodgkin Lymphoma (NHL) Market Challenges
Table 13. Non Hodgkin Lymphoma (NHL) Market Restraints
Table 14. Global Non Hodgkin Lymphoma (NHL) Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Non Hodgkin Lymphoma (NHL) Market Share by Players (2016-2021)
Table 16. Global Top Non Hodgkin Lymphoma (NHL) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non Hodgkin Lymphoma (NHL) as of 2020)
Table 17. Ranking of Global Top Non Hodgkin Lymphoma (NHL) Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Non Hodgkin Lymphoma (NHL) Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non Hodgkin Lymphoma (NHL) Product Solution and Service
Table 21. Date of Enter into Non Hodgkin Lymphoma (NHL) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2016-2021)
Table 25. Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Non Hodgkin Lymphoma (NHL) Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2016-2021)
Table 29. Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2022-2027) & (US$ Million)
Table 61. F. Hoffmann-La Roche Company Details
Table 62. F. Hoffmann-La Roche Business Overview
Table 63. F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product
Table 64. F. Hoffmann-La Roche Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 65. F. Hoffmann-La Roche Recent Development
Table 66. Johnson & Johnson Company Details
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product
Table 69. Johnson & Johnson Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 70. Johnson & Johnson Recent Development
Table 71. Merck Company Details
Table 72. Merck Business Overview
Table 73. Merck Non Hodgkin Lymphoma (NHL) Product
Table 74. Merck Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 75. Merck Recent Development
Table 76. Bristol Myers Squibb Company Details
Table 77. Bristol Myers Squibb Business Overview
Table 78. Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product
Table 79. Bristol Myers Squibb Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 80. Bristol Myers Squibb Recent Development
Table 81. Celgene Company Details
Table 82. Celgene Business Overview
Table 83. Celgene Non Hodgkin Lymphoma (NHL) Product
Table 84. Celgene Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 85. Celgene Recent Development
Table 86. Eli Lilly Company Details
Table 87. Eli Lilly Business Overview
Table 88. Eli Lilly Non Hodgkin Lymphoma (NHL) Product
Table 89. Eli Lilly Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 90. Eli Lilly Recent Development
Table 91. GlaxoSmithKline Company Details
Table 92. GlaxoSmithKline Business Overview
Table 93. GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product
Table 94. GlaxoSmithKline Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 95. GlaxoSmithKline Recent Development
Table 96. Bayer Company Details
Table 97. Bayer Business Overview
Table 98. Bayer Revenue in Non Hodgkin Lymphoma (NHL) Business (2016-2021) & (US$ Million)
Table 99. Bayer Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non Hodgkin Lymphoma (NHL) Market Share by Type: 2020 VS 2027
Figure 2. Standard Features
Figure 3. Exellent Features
Figure 4. Global Non Hodgkin Lymphoma (NHL) Market Share by Application: 2020 VS 2027
Figure 5. Hosptial Case Studies
Figure 6. Clinic Case Studies
Figure 7. Non Hodgkin Lymphoma (NHL) Report Years Considered
Figure 8. Global Non Hodgkin Lymphoma (NHL) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Non Hodgkin Lymphoma (NHL) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Non Hodgkin Lymphoma (NHL) Market Share by Regions: 2020 VS 2027
Figure 11. Global Non Hodgkin Lymphoma (NHL) Market Share by Regions (2022-2027)
Figure 12. Global Non Hodgkin Lymphoma (NHL) Market Share by Players in 2020
Figure 13. Global Top Non Hodgkin Lymphoma (NHL) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non Hodgkin Lymphoma (NHL) as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Non Hodgkin Lymphoma (NHL) Revenue in 2020
Figure 15. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2016-2021)
Figure 16. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2022-2027)
Figure 17. North America Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Non Hodgkin Lymphoma (NHL) Market Share by Type (2016-2027)
Figure 19. North America Non Hodgkin Lymphoma (NHL) Market Share by Application (2016-2027)
Figure 20. North America Non Hodgkin Lymphoma (NHL) Market Share by Country (2016-2027)
Figure 21. United States Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Non Hodgkin Lymphoma (NHL) Market Share by Type (2016-2027)
Figure 25. Europe Non Hodgkin Lymphoma (NHL) Market Share by Application (2016-2027)
Figure 26. Europe Non Hodgkin Lymphoma (NHL) Market Share by Country (2016-2027)
Figure 27. Germany Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Share by Region (2016-2027)
Figure 37. China Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Non Hodgkin Lymphoma (NHL) Market Share by Type (2016-2027)
Figure 45. Latin America Non Hodgkin Lymphoma (NHL) Market Share by Application (2016-2027)
Figure 46. Latin America Non Hodgkin Lymphoma (NHL) Market Share by Country (2016-2027)
Figure 47. Mexico Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Country (2016-2027)
Figure 53. Turkey Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. F. Hoffmann-La Roche Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 57. Johnson & Johnson Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 58. Merck Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 59. Bristol Myers Squibb Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 60. Celgene Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 61. Eli Lilly Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 63. Bayer Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2016-2021)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

---